

EMA/645489/2010

European Medicines Agency decision

P/192/2010

of 26 October 2010

on the acceptance of a modification of an agreed paediatric investigation plan for doripenem monohydrate (Doribax), (EMA-000015-PIP01-07-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/192/2010

of 26 October 2010

on the acceptance of a modification of an agreed paediatric investigation plan for doripenem monohydrate (Doribax), (EMA-000015-PIP01-07-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/14/2008 issued on 31 March 2008, and the decision P/151/2009 issued on 7 August 2009,

Having regard to the application submitted by Janssen-Cilag International N.V. on 28 June 2010 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 10 September 2010, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for doripenem monohydrate (Doribax), powder for solution for infusion, intravenous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Janssen-Cilag International N.V., Turnhoutseweg 30, Beerse, B-2340, Belgium.

Done at London, 26 October 2010

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)

EMA/PDCO/542892/2010

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMA-000015-PIP01-07-M02

Scope of the application

Active substance(s):

Doripenem monohydrate

Invented name:

Doribax

Condition(s):

Treatment of bacterial infections:

- nosocomial pneumonia, including ventilator-associated pneumonia
- complicated intra-abdominal infections
- complicated urinary tract infections, including complicated and uncomplicated pyelonephritis and cases with concurrent bacteremia

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Powder for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Janssen-Cilag International N.V.

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Janssen-Cilag International N.V. submitted to the European Medicines Agency on 28 June 2010 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/14/2008 issued on 31 March 2008, and the decision P/151/2009 issued on 7 August 2009.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 15 July 2010.

Scope of the modification

Some measures and timelines of the original Opinion have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree to changes to the paediatric investigation plan.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

London, 10 September 2010

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

Annex I

The measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

Not applicable

2. Paediatric Investigation Plan

2.1. Condition:

Treatment of bacterial infections:

- nosocomial pneumonia, including ventilator-associated pneumonia
- complicated intra-abdominal infections
- complicated urinary tract infections, including complicated and uncomplicated pyelonephritis and cases with concurrent bacteremia

2.1.1. Indication(s) targeted by the PIP

Treatment of:

- nosocomial pneumonia, including ventilator-associated pneumonia,
- complicated intra-abdominal infections,
- complicated urinary tract infections, including complicated and uncomplicated pyelonephritis and cases with concurrent bacteremia.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder for solution for infusion

2.1.4. Studies

Area	Subarea	Number	Description
Clinical	PK, safety and tolerability	2	1) Multi-centre, open-label, study to evaluate the PK, safety/ tolerability and to identify the appropriate dose for children from 3 months to less than 18 years. 2) Multi-centre, open-label, study to evaluate PK, safety and tolerability in neonates including preterm infants with GA below 28 weeks, and in infants less than 3 months old.
	Descriptive safety and Efficacy	4	1) Randomized double-blind, multicenter, comparative study in hospitalized children 3 months to less than 18 years of age with complicated intra abdominal infections (cIAI) requiring intravenous antibiotic therapy. 2) Randomized, double-blind, multicenter, comparative study in hospitalized children 3 months to less than 18 years of age with complicated urinary tract infections (cUTI) requiring intravenous antibiotic therapy. 3) Randomized, double-blind, multicenter, comparative study in hospitalized children 3 months to less than 18 years of age with pneumonia requiring intravenous antibiotic therapy.

			4) Multi-centre, open-label, descriptive safety, tolerability and efficacy study in neonates including preterm infants with GA below 28 weeks, and in infants less than 3 months of age.
--	--	--	--

3. Follow-up, completion and deferral of PIP

Measures to address long term follow-up of potential safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2012
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s)

Treatment of

- Nosocomial pneumonia (including ventilator–associated pneumonia)
- Complicated intra-abdominal infections
- Complicated urinary tract infections

Authorised indications:

Doribax is indicated for the treatment of the following infections in adults:

- Nosocomial pneumonia (including ventilator–associated pneumonia)
- Complicated intra-abdominal infections
- Complicated urinary tract infections

EU Number	Invented name	Strength	Pharmaceutical form	Route of administration	Packaging	Content (concentration)	Package size
EU/1/08/467/001	Doribax	500 mg	Powder for solution for infusion	Intravenous use	vial (glass)		10 vials
EU/1/08/467/002	Doribax	250 mg	Powder for solution for infusion	Intravenous use	vial (glass)		10 vials